Dare Bioscience (DARE)
Market Price (12/27/2025): $2.11 | Market Cap: $26.9 MilSector: Health Care | Industry: Biotechnology
Dare Bioscience (DARE)
Market Price (12/27/2025): $2.11Market Cap: $26.9 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -73% | Weak multi-year price returns2Y Excs Rtn is -89%, 3Y Excs Rtn is -161% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is -57,130 |
| Megatrend and thematic driversMegatrends include Women's Health Innovation. Themes include Reproductive Health Therapies, Sexual Health Solutions, and Gynecological Disorder Treatments. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -17 Mil | |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -103%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -35%, Rev Chg QQuarterly Revenue Change % is -95% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -68% | ||
| Key risksDARE key risks include [1] acute financial distress and high bankruptcy risk raising substantial doubt about its ability to continue as a going concern, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -73% |
| Megatrend and thematic driversMegatrends include Women's Health Innovation. Themes include Reproductive Health Therapies, Sexual Health Solutions, and Gynecological Disorder Treatments. |
| Weak multi-year price returns2Y Excs Rtn is -89%, 3Y Excs Rtn is -161% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is -57,130 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -17 Mil |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -103%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -35%, Rev Chg QQuarterly Revenue Change % is -95% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -68% |
| Key risksDARE key risks include [1] acute financial distress and high bankruptcy risk raising substantial doubt about its ability to continue as a going concern, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
The 6.4% movement in Dare Bioscience (DARE) stock from August 31, 2025, to December 27, 2025, can be attributed to several key developments:
<br><br>
<b>1. Commercial Rollout of DARE to PLAYâ„¢ Sildenafil Cream:</b> The company announced on December 10, 2025, that DARE to PLAYâ„¢ Sildenafil Cream was available for pre-order by prescription and had begun its commercial rollout in select states via a 503B outsourcing facility. This represented a significant commercial milestone, following earlier indications in August and November that the product was on track for a Q4 2025 launch and poised for near-term revenue generation.
<br><br>
<b>2. Substantial Non-Dilutive Grant Funding:</b> Daré Bioscience secured significant non-dilutive grant funding during this period. This included a $4 million installment in October 2025, contributing to a total of $41.8 million received from a commitment of up to $49 million for a smart drug delivery device for contraception. Additionally, the company announced receiving $3.6 million in further grant funding in November 2025.
<br><br>
<b>3. Positive Interim Data for Ovaprene® Phase 3 Study:</b> The Ovaprene® Phase 3 clinical study received a positive interim recommendation from its Data and Safety Monitoring Board (DSMB), indicating support for the continuation of the trial. This progress in a key pipeline asset was highlighted in both the Q2 and Q3 2025 corporate updates.
<br><br>
<b>4. Return of Rights to Ovaprene®:</b> On December 1, 2025, Daré Bioscience announced the return of rights to Ovaprene®, an investigational hormone-free monthly intravaginal contraceptive. While the Phase 3 program continued, this strategic move was described as positioning the asset for value-maximization, bolstered by positive interim data and existing grant funding.
<br><br>
<b>5. Strengthening Financial Position and Strategic Execution:</b> The company bolstered its financial standing, reporting approximately $23.1 million in cash and cash equivalents as of September 30, 2025. Management consistently emphasized a "dual-path strategy," focusing on generating near-term commercial revenue through products like DARE to PLAY while simultaneously advancing long-term innovation in women's health. This strategy also outlined plans for the future introduction of nonprescription vaginal probiotics.
Show moreStock Movement Drivers
Fundamental Drivers
The 2.9% change in DARE stock from 9/26/2025 to 12/26/2025 was primarily driven by a 222.8% change in the company's Total Revenues ($ Mil).| 9262025 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 2.09 | 2.15 | 2.87% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | -0.02 | -0.06 | 222.75% |
| P/S Multiple | -1047.44 | -480.02 | -54.17% |
| Shares Outstanding (Mil) | 8.87 | 12.76 | -43.78% |
| Cumulative Contribution | -16.85% |
Market Drivers
9/26/2025 to 12/26/2025| Return | Correlation | |
|---|---|---|
| DARE | 2.9% | |
| Market (SPY) | 4.3% | 18.6% |
| Sector (XLV) | 15.2% | 19.1% |
Fundamental Drivers
The -9.1% change in DARE stock from 6/27/2025 to 12/26/2025 was primarily driven by a -320.5% change in the company's Total Revenues ($ Mil).| 6272025 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 2.37 | 2.15 | -9.09% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 0.03 | -0.06 | -320.50% |
| P/S Multiple | 799.54 | -480.02 | -160.04% |
| Shares Outstanding (Mil) | 8.76 | 12.76 | -45.62% |
| Cumulative Contribution | -28.01% |
Market Drivers
6/27/2025 to 12/26/2025| Return | Correlation | |
|---|---|---|
| DARE | -9.1% | |
| Market (SPY) | 12.6% | 10.0% |
| Sector (XLV) | 17.0% | 16.7% |
Fundamental Drivers
The -34.8% change in DARE stock from 12/26/2024 to 12/26/2025 was primarily driven by a -3306.5% change in the company's P/S Multiple.| 12262024 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 3.30 | 2.15 | -34.85% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 1.88 | -0.06 | -103.04% |
| P/S Multiple | 14.97 | -480.02 | -3306.50% |
| Shares Outstanding (Mil) | 8.53 | 12.76 | -49.45% |
| Cumulative Contribution | -50.78% |
Market Drivers
12/26/2024 to 12/26/2025| Return | Correlation | |
|---|---|---|
| DARE | -34.8% | |
| Market (SPY) | 15.8% | 8.0% |
| Sector (XLV) | 13.3% | 15.4% |
Fundamental Drivers
The -78.7% change in DARE stock from 12/27/2022 to 12/26/2025 was primarily driven by a -6837.0% change in the company's P/S Multiple.| 12272022 | 12262025 | Change | |
|---|---|---|---|
| Stock Price ($) | 10.08 | 2.15 | -78.67% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 10.00 | -0.06 | -100.57% |
| P/S Multiple | 7.13 | -480.02 | -6837.02% |
| Shares Outstanding (Mil) | 7.07 | 12.76 | -80.45% |
| Cumulative Contribution | -92.48% |
Market Drivers
12/27/2023 to 12/26/2025| Return | Correlation | |
|---|---|---|
| DARE | -47.0% | |
| Market (SPY) | 48.0% | 7.9% |
| Sector (XLV) | 18.2% | 14.0% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| DARE Return | 63% | 49% | -58% | -63% | -16% | -30% | -78% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| DARE Win Rate | 33% | 42% | 8% | 17% | 42% | 50% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| DARE Max Drawdown | -4% | -10% | -59% | -65% | -27% | -48% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL. See DARE Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | DARE | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -90.3% | -25.4% |
| % Gain to Breakeven | 934.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -53.5% | -33.9% |
| % Gain to Breakeven | 114.8% | 51.3% |
| Time to Breakeven | 302 days | 148 days |
| 2018 Correction | ||
| % Loss | -98.1% | -19.8% |
| % Gain to Breakeven | 5169.8% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
Dare Bioscience's stock fell -90.3% during the 2022 Inflation Shock from a high on 1/20/2021. A -90.3% loss requires a 934.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Here are 1-3 brief analogies for Dare Bioscience (DARE):
A specialized Pfizer focused on women's health.
A clinical-stage Moderna developing novel women's health products.
A focused Johnson & Johnson dedicated to innovations in women's reproductive and sexual health.
AI Analysis | Feedback
Here are the major products of Dare Bioscience:- Ovaprene: A novel hormone-free, monthly contraceptive intravaginal ring designed to prevent pregnancy.
- DARE-VVA1: A non-hormonal, investigational ovule developed for the treatment of vulvovaginal atrophy (VVA).
- Sildenafil Cream, 3.6% (DARE-GSD): An investigational topical cream designed to treat female sexual arousal disorder (FSAD).
- DARE-BV1: An investigational thermosetting hydrogel being developed for the treatment of bacterial vaginosis.
AI Analysis | Feedback
```htmlDare Bioscience (symbol: DARE) is a clinical-stage biopharmaceutical company focused on women's health. As of its current operational status, the company does not have any products approved for commercialization and therefore does not generate product revenue from sales to other companies or individuals.
Consequently, Dare Bioscience does not currently have any major customers to list, as its revenue is primarily derived from collaboration arrangements and grants rather than from the sale of commercial products.
```AI Analysis | Feedback
nullAI Analysis | Feedback
Dare Bioscience (symbol: DARE) Management Team:Sabrina Johnson, President & CEO, Principal Financial Officer
Sabrina Johnson is the founder and CEO of Daré Bioscience, which she established in 2015. She has a robust background spanning over 25 years in life sciences, including finance, global marketing, product development, and bench research. Prior to founding Daré, she served as President of WomanCare Global Trading, a global provider of women's health products. She also held CFO/CAO positions at the California Institute for Biomedical Research and CFO/COO roles at Cypress Bioscience, Inc. At Cypress Bioscience, she was instrumental in executing mergers, acquisitions, and divestitures, including a transaction that resulted in a 160% premium for shareholders with a deal valued over $250 million when the company was sold. She has also held marketing and sales positions at Advanced Tissue Sciences and began her biotechnology career as a research scientist at Baxter Healthcare.
MarDee Haring-Layton, Chief Accounting Officer
MarDee Haring-Layton joined Daré Bioscience in January 2018 and has been the Chief Accounting Officer since January 2024, also serving as the principal accounting officer. She previously held the role of Vice President, Accounting & Finance since October 2018. Ms. Haring-Layton is an experienced finance and accounting executive with over 20 years of experience in financial reporting and accounting operations across both public and private companies, including a background in Big 4 public accounting. Before joining Daré, she served as Chief Financial Officer of e.Digital Corporation, a publicly traded IP licensing and development company, from 2010 to 2017.
David Friend, Ph.D., Chief Scientific Officer
David Friend, Ph.D., was appointed Chief Scientific Officer of Daré Bioscience in June 2018. He brings extensive expertise in product development, covering stages from pre-IND through Phase III and NDA submissions to the FDA. His background includes a deep understanding of CMC, intellectual property, and product formulation science, particularly in vaginal drug delivery systems such as gels, creams, tablets, intravaginal rings, and controlled release polymers. Prior to Daré, Dr. Friend served as Chief Scientific Officer at Evofem Biosciences and as Director of Product Development at CONRAD, an organization focused on contraceptive research. He also held the position of Vice President of Research at Vyteris, a company developing transdermal delivery systems, and has experience at other pharmaceutical companies including Delsys Pharmaceutical, Vascular Therapeutics, CIBUS Pharmaceuticals, and SRI International.
Mark Walters, Vice President - Operations
Mark Walters has served as the Vice President - Operations for Daré Bioscience since 2015. His role involves overseeing the company's operational activities.
Elizabeth Proos, Vice President, Product Development
Elizabeth Proos joined Daré Bioscience in November 2019 following the acquisition of DARE MB Inc. and currently serves as the Vice President of Product Development. In this role, she is responsible for technical and strategic product development, implementing best practices in product development and program management. Ms. Proos also leads the strategy and product development for DARE-LARC1, a user-controlled, long-acting, reversible contraceptive, and manages a cross-functional R&D and product development team along with key external partners. Her career spans over 23 years in drug delivery science and the development of combination products and medical devices, where she has advanced novel products through clinical development across various therapeutic areas. Prior to Daré Bioscience, she held leadership and technical positions at BD, Lantheus Medical Imaging, Epic Therapeutics (a subsidiary of Baxter Healthcare), and Etex Corporation.
AI Analysis | Feedback
The key risks to Dare Bioscience (DARE) are primarily centered around its financial viability, regulatory hurdles for its product pipeline, and its listing status on Nasdaq.
- Financial Health and Going Concern: Dare Bioscience faces substantial doubt about its ability to continue as a going concern within the next 12 months. This is due to ongoing losses, negative operating cash flow, and uncertainty regarding the timing and magnitude of future revenue. The company has a reported working capital deficit of approximately $12.6 million as of June 30, 2025, and is characterized by a rapid cash burn. Its Altman Z-Score of -9.68 indicates a high risk of bankruptcy within two years. The company's minimal revenue, such as $2,262 in Q3 2025, further underscores its financial challenges and reliance on grant funding and partnerships to advance its pipeline.
- Regulatory and Commercialization Challenges for Products: A significant risk stems from the regulatory pathway and commercialization of its product candidates. For instance, DARE to PLAY Sildenafil cream, a potential "near-term revenue driver," is currently available as a Section 503B compounded product, meaning it is not FDA approved. This status can raise concerns among consumers and healthcare providers regarding its safety and effectiveness. There is also a risk that the FDA could change the conditions under which 503B-registered outsourcing facilities can compound such drug substances or distribute compounded products. Furthermore, Dare Bioscience has limited experience and infrastructure for commercializing products, which could impede the successful launch and market acceptance of its offerings, even if approved.
- Nasdaq Delisting Risk: Dare Bioscience is facing potential delisting from the Nasdaq Capital Market. The company received a notification from Nasdaq for non-compliance with the exchange's minimum market value requirement of $35 million. While Dare Bioscience plans to request a hearing to prevent delisting, there is no guarantee that the Nasdaq Hearing Panel will grant additional time or that the company will be able to meet the compliance requirement within any extension period.
AI Analysis | Feedback
nullAI Analysis | Feedback
Dare Bioscience (symbol: DARE) focuses on women's reproductive health, with several products in its pipeline targeting significant addressable markets.
Main Products and Addressable Markets:
-
XACIATO (clindamycin phosphate vaginal gel) for Bacterial Vaginosis (BV):
The global bacterial vaginosis treatment market was valued at approximately USD 1.23 billion in 2024 and is projected to reach USD 2.37 billion by 2032. Other estimates for the global market include USD 3.79 billion in 2025, reaching USD 6.88 billion by 2032. The bacterial vaginosis market across the top 7 markets (US, EU4, UK, and Japan) was valued at USD 806.4 million in 2024 and is projected to reach USD 1,450.4 million by 2035. North America dominates the bacterial vaginosis Rx drug market, holding a substantial 40.5% market share in 2023.
-
Ovaprene (hormone-free monthly intravaginal contraceptive):
This product addresses the non-hormonal contraceptives market. The global non-hormonal contraceptives market size was valued at USD 19.9 billion in 2024 and is expected to reach USD 39.1 billion by 2034. Another report estimates the global non-hormonal contraception market at USD 30.67 billion in 2023, poised to grow to USD 54.06 billion by 2032. The U.S. non-hormonal contraceptives market accounted for USD 5.8 billion in 2024.
-
Sildenafil Cream, 3.6% (for Female Sexual Arousal Disorder - FSAD):
This product targets the female sexual dysfunction treatment market. The global female sexual dysfunction treatment market size was valued at USD 489.6 million in 2024 and is projected to grow to USD 1,329.5 million by 2032. Other estimates for the global market include USD 542.97 million in 2024, growing to USD 1,443.44 million by 2032. The North American market for female sexual dysfunction treatment was valued at USD 435.9 million in 2024 and is anticipated to continue to dominate. The U.S. female sexual dysfunction treatment market size is projected to grow significantly, reaching an estimated value of USD 782.3 million by 2032.
-
DARE-HRT1 (combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy, including vulvar and vaginal atrophy):
The global vulvar and vaginal atrophy therapy market is projected to reach US$3.8 billion in 2025 and is expected to reach US$5.4 billion by 2032. The atrophic vaginitis treatment industry is valued at USD 3.21 billion in 2025 and is projected to reach USD 6.93 billion by 2035 (global). The U.S. vaginal atrophy treatment market size was valued at USD 1.19 billion in 2024 and is projected to grow to USD 1.63 billion by 2032. Dare Bioscience also anticipates that its proprietary monthly hormone therapy via the 503B compounding pathway creates entry into the estimated USD 4.5 billion compounded hormone therapy market, likely referring to the U.S. market.
-
Programs for Preterm Birth (e.g., DARE-FRT1/PTB1):
The global preterm labor treatment market size was valued at USD 1.20 billion in 2024 and is expected to grow to USD 2.63 billion by 2033. Another estimate for the global premature labor treatment market size is USD 1,603.4 million in 2025, reaching USD 3,352.96 million by 2033. The preterm births and PROM testing market is projected to grow from USD 2.0 billion in 2025 to USD 2.7 billion by 2035 (global). North America holds 33.05% of the global premature labor treatment market in 2025.
-
Fertility Products (general, including IVF):
The global fertility services market was estimated at USD 42.23 billion in 2023 and is projected to reach USD 70.27 billion by 2030. The global in vitro fertilization (IVF) market size was estimated at USD 25.3 billion in 2023 and is projected to reach USD 37.4 billion by 2030. The U.S. in-vitro fertilization services market was valued at USD 5,910.98 million in 2024 and is projected to reach USD 13,944.38 million by 2032.
AI Analysis | Feedback
Dare Bioscience (DARE) anticipates several key drivers for future revenue growth over the next two to three years, primarily stemming from the commercialization of its pipeline products in women's health:
- Launch of DARE to PLAYâ„¢ Sildenafil Cream: The company expects its first revenue-generating product, DARE to PLAYâ„¢ Sildenafil Cream, to launch in the fourth quarter of 2025 through a 503B compounding pathway. This product is designed for topical, on-demand use in women with female sexual arousal disorder.
- Commercialization of DARE-HRT1: Daré Bioscience plans to introduce DARE-HRT1, a proprietary monthly hormone therapy delivered via a vaginal ring, by late 2026. This product aims to enter the estimated $4.5 billion compounded hormone therapy market, expanding the company's addressable market to include menopause symptom relief.
- Commercialization of Vaginal Probiotics: Following the availability of DARE to PLAY Sildenafil Cream, Daré Bioscience intends to commercialize vaginal probiotics in the consumer health market.
- Advancement of Ovaprene®: While still in clinical development, the investigational hormone-free intravaginal contraceptive, Ovaprene®, has shown positive interim results in its Phase 3 study and is a significant asset that could drive future revenue upon successful completion of trials and market entry. This product represents a first-in-category, hormone-free solution.
- Progress in Grant-Funded Programs: Continued progress in grant-funded pipeline programs, such as DARE-HPV for human papillomavirus infection and DARE-LARC1 for long-acting contraception, could lead to future product commercialization and revenue streams beyond the initial launches.
AI Analysis | Feedback
Share Issuance
- Dare Bioscience entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC in October 2024, authorizing the sale of up to $15 million in common stock over a 24-month period.
- In August/September 2023, the company completed a registered direct offering of common stock and warrants, resulting in $7.0 million in aggregate gross proceeds.
- Post Q2 2025 (July 2025), Dare Bioscience raised $17.6 million in net proceeds through common stock sales, primarily from At-The-Market (ATM) offerings.
- A 1-for-12 reverse stock split was implemented in July 2024 to address Nasdaq's minimum bid price requirement.
Inbound Investments
- As of October 2025, Dare Bioscience received a $4.0 million non-dilutive grant installment, bringing the total received to approximately $41.8 million out of a potential $49 million commitment to support the DARE-LARC1 contraceptive program.
- In December 2023, the company secured a royalty-backed financing agreement providing $5 million at closing and the option for an additional $7 million in tranches against future XACIATO royalties and milestones.
- In 2024, the company received $3.5 million in grant funding as part of the multi-year grant agreement for DARE-LARC1.
Capital Expenditures
- Over the last 12 months (as of October 2025), Dare Bioscience's capital expenditures were approximately -$284,459.
- The company's primary capital usage focuses on staff-related expenses, clinical trials, regulatory activities, contract manufacturing services, and third-party research and development, rather than significant investments in physical assets.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to DARE. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.1% | 21.1% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -6.7% | -6.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 16.7% | 16.7% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 11.8% | 11.8% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Dare Bioscience
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 51.32 |
| Mkt Cap | 158.8 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.2% |
| Rev Chg 3Y Avg | 2.2% |
| Rev Chg Q | 8.3% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Mgn LTM | 17.7% |
| Op Mgn 3Y Avg | 16.4% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 20.6% |
| CFO/Rev 3Y Avg | 21.4% |
| FCF/Rev LTM | 18.1% |
| FCF/Rev 3Y Avg | 18.6% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Business of identifying, developing and commercializing pharmaceutical products that target unmet | 3 | ||||
| Total | 3 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Business of identifying, developing and commercializing pharmaceutical products that target unmet | -31 | ||||
| Total | -31 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Business of identifying, developing and commercializing pharmaceutical products that target unmet | -30 | ||||
| Total | -30 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Single Segment | 44 | 56 | 8 | 7 | |
| Total | 44 | 56 | 8 | 7 |
Price Behavior
| Market Price | $2.15 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 04/10/2014 | |
| Distance from 52W High | -36.4% | |
| 50 Days | 200 Days | |
| DMA Price | $1.96 | $2.43 |
| DMA Trend | down | down |
| Distance from DMA | 9.7% | -11.4% |
| 3M | 1YR | |
| Volatility | 66.4% | 54.8% |
| Downside Capture | 155.69 | 77.11 |
| Upside Capture | 138.13 | 23.02 |
| Correlation (SPY) | 18.6% | 7.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.43 | 1.76 | 1.54 | 0.85 | 0.30 | 0.51 |
| Up Beta | 0.94 | 0.06 | 0.29 | -0.46 | -0.01 | 0.36 |
| Down Beta | 2.23 | 2.46 | 2.74 | 1.93 | 0.18 | 0.45 |
| Up Capture | 239% | 119% | 81% | -6% | 17% | 5% |
| Bmk +ve Days | 12 | 25 | 38 | 73 | 141 | 426 |
| Stock +ve Days | 8 | 17 | 29 | 56 | 108 | 330 |
| Down Capture | 293% | 227% | 169% | 161% | 102% | 101% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 11 | 21 | 28 | 61 | 118 | 374 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of DARE With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| DARE | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -20.7% | 15.1% | 17.8% | 72.1% | 8.6% | 4.4% | -8.3% |
| Annualized Volatility | 57.4% | 17.2% | 19.4% | 19.3% | 15.2% | 17.0% | 35.0% |
| Sharpe Ratio | -0.20 | 0.65 | 0.72 | 2.70 | 0.34 | 0.09 | -0.08 |
| Correlation With Other Assets | 16.3% | 8.5% | 5.4% | 2.0% | 9.6% | 8.2% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of DARE With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| DARE | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -30.8% | 8.4% | 14.7% | 18.7% | 11.5% | 4.6% | 30.8% |
| Annualized Volatility | 79.7% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.7% |
| Sharpe Ratio | -0.12 | 0.40 | 0.70 | 0.97 | 0.50 | 0.16 | 0.57 |
| Correlation With Other Assets | 14.4% | 15.8% | 4.2% | 4.3% | 11.4% | 12.4% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of DARE With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| DARE | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -41.3% | 9.9% | 14.8% | 15.3% | 7.0% | 5.3% | 69.2% |
| Annualized Volatility | 115.9% | 16.6% | 18.0% | 14.7% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.01 | 0.49 | 0.71 | 0.86 | 0.32 | 0.22 | 0.90 |
| Correlation With Other Assets | 12.3% | 13.3% | 1.5% | 3.1% | 8.9% | 4.6% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/13/2025 | -1.6% | -13.8% | 19.6% |
| 8/14/2025 | 6.3% | 1.4% | -1.9% |
| 3/31/2025 | 0.3% | -0.2% | 2.1% |
| 11/14/2024 | -10.0% | -9.4% | -10.8% |
| 8/12/2024 | 20.0% | -0.6% | -6.9% |
| 3/28/2024 | -10.7% | -7.3% | -44.3% |
| 11/9/2023 | -6.9% | -3.2% | -18.0% |
| 8/10/2023 | -2.3% | -0.3% | -20.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 6 | 4 | 3 |
| # Negative | 6 | 8 | 9 |
| Median Positive | 2.6% | 2.4% | 2.1% |
| Median Negative | -4.7% | -4.5% | -12.0% |
| Max Positive | 20.0% | 11.6% | 19.6% |
| Max Negative | -10.7% | -13.8% | -44.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11132025 | 10-Q 9/30/2025 |
| 6302025 | 8142025 | 10-Q 6/30/2025 |
| 3312025 | 5132025 | 10-Q 3/31/2025 |
| 12312024 | 3312025 | 10-K 12/31/2024 |
| 9302024 | 11142024 | 10-Q 9/30/2024 |
| 6302024 | 8122024 | 10-Q 6/30/2024 |
| 3312024 | 5142024 | 10-Q 3/31/2024 |
| 12312023 | 3282024 | 10-K 12/31/2023 |
| 9302023 | 11092023 | 10-Q 9/30/2023 |
| 6302023 | 8102023 | 10-Q 6/30/2023 |
| 3312023 | 5112023 | 10-Q 3/31/2023 |
| 12312022 | 3302023 | 10-K 12/31/2022 |
| 9302022 | 11102022 | 10-Q 9/30/2022 |
| 6302022 | 8092022 | 10-Q 6/30/2022 |
| 3312022 | 5122022 | 10-Q 3/31/2022 |
| 12312021 | 3312022 | 10-K 12/31/2021 |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.